Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study.

Sarid-Segal O, Piechniczek-Buczek J, Knapp C, Afshar M, Devine E, Sickles L, Uwodukunda E, Richambault C, Koplow J, Ciraulo D.

Am J Drug Alcohol Abuse. 2008;34(4):441-7. doi: 10.1080/00952990802082180.

2.

A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.

Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tiouririne NA, Johnson B, Pettinati H, Strain EC, Devine E, Brunette MF, Kampman K, A Tompkins D, Stout R; NCIG 002 Study Group..

Alcohol Clin Exp Res. 2012 Aug;36(8):1421-30. doi: 10.1111/j.1530-0277.2011.01716.x. Epub 2012 Feb 10.

3.

Levetiracetam in the treatment of alcohol dependence: toward the end of the story?

Le Strat Y.

Alcohol Clin Exp Res. 2012 Aug;36(8):1309-10. doi: 10.1111/j.1530-0277.2012.01891.x. Epub 2012 Jul 23.

PMID:
22823576
4.

The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers.

Mitchell JM, Grossman LE, Coker AR, Messing RO.

J Clin Psychopharmacol. 2012 Apr;32(2):269-72. doi: 10.1097/JCP.0b013e318248ba69.

PMID:
22367657
5.

Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review.

Mariani JJ, Levin FR.

Am J Drug Alcohol Abuse. 2008;34(6):683-91. doi: 10.1080/00952990802308213.

6.

Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial.

Richter C, Effenberger S, Bschor T, Bonnet U, Haasen C, Preuss UW, Heinz A, Förg A, Volkmar K, Glauner T, Schaefer M.

J Clin Psychopharmacol. 2012 Aug;32(4):558-62. doi: 10.1097/JCP.0b013e31825e213e.

PMID:
22722516
7.

Efficacy and safety of levetiracetam for outpatient alcohol detoxification.

Müller CA, Schäfer M, Schneider S, Heimann HM, Hinzpeter A, Volkmar K, Förg A, Heinz A, Hein J.

Pharmacopsychiatry. 2010 Jul;43(5):184-9. doi: 10.1055/s-0030-1249098. Epub 2010 May 25.

PMID:
20503149
8.

Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with levetiracetam: a preliminary study.

Zalewska-Kaszubska J, Bajer B, Czarnecka E, Dyr W, Gorska D.

Physiol Behav. 2011 Mar 28;102(5):538-41. doi: 10.1016/j.physbeh.2010.12.021. Epub 2010 Dec 25.

PMID:
21187108
9.

Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain.

Sills GJ, Leach JP, Fraser CM, Forrest G, Patsalos PN, Brodie MJ.

Eur J Pharmacol. 1997 Apr 23;325(1):35-40.

PMID:
9151936
10.

Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders.

Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC, Oscar-Berman M, Surprise C, Colaneri L, Putnam M, Waters M, Richambault C.

J Clin Psychopharmacol. 2015 Feb;35(1):34-42. doi: 10.1097/JCP.0000000000000246.

11.

[Levetiracetam: a molecule with a novel mechanism of action in the pharmaceutical treatment of epilepsy].

Szökó E.

Ideggyogy Sz. 2002 May 20;55(5-6):195-6. Review. Hungarian. No abstract available.

PMID:
12122879
12.

An open-label pilot study of levetiracetam for essential tremor.

Ondo WG, Jimenez JE, Vuong KD, Jankovic J.

Clin Neuropharmacol. 2004 Nov-Dec;27(6):274-7.

PMID:
15613931
13.

A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy.

Nakken KO, Eriksson AS, Lossius R, Johannessen SI.

Seizure. 2003 Jan;12(1):42-6.

14.

The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation.

Palma E, Ragozzino D, Di Angelantonio S, Mascia A, Maiolino F, Manfredi M, Cantore G, Esposito V, Di Gennaro G, Quarato P, Miledi R, Eusebi F.

Epilepsia. 2007 Oct;48(10):1842-9. Epub 2007 May 23.

15.

Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy.

Klitgaard H, Matagne A, Gobert J, Wülfert E.

Eur J Pharmacol. 1998 Jul 24;353(2-3):191-206.

PMID:
9726649
16.

Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.

Beran RG, Berkovic SF, Black AB, Danta G, Hiersemenzel R, Schapel GJ, Vajda FJ.

Epilepsy Res. 2005 Jan;63(1):1-9. Epub 2005 Jan 6.

PMID:
15716083
17.

Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy.

Specchio N, Boero G, Michelucci R, Gambardella A, Giallonardo AT, Fattouch J, Di Bonaventura C, de Palo A, Ladogana M, Lamberti P, Vigevano F, La Neve A, Specchio LM.

Epilepsia. 2008 Apr;49(4):663-9. doi: 10.1111/j.1528-1167.2007.01523.x. Epub 2008 Feb 5.

18.

Pilot tolerability and effectiveness study of levetiracetam for postherpetic neuralgia.

Rowbotham MC, Manville NS, Ren J.

Neurology. 2003 Sep 23;61(6):866-7. No abstract available.

PMID:
14504347
19.

Levetiracetam: treatment in epilepsy.

Ben-Menachem E.

Expert Opin Pharmacother. 2003 Nov;4(11):2079-88. Review.

PMID:
14596661
20.

Levetiracetam in three cases of progressive myoclonus epilepsy.

Papacostas S, Kkolou E, Papathanasiou E.

Pharm World Sci. 2007 Jun;29(3):164-6. Epub 2007 Jan 23.

PMID:
17242859

Supplemental Content

Support Center